Association of tumor growth rate with overall survival and recurrence among patients with laryngeal squamous cell carcinoma.

IF 2.3 3区医学 Q1 OTORHINOLARYNGOLOGY

Head and Neck-Journal for the Sciences and Specialties of the Head and Neck Pub Date : 2024-07-24 DOI:10.1002/hed.27888

Faye G Zhang, Shankar Viswanathan, Chenxin Zhang, Richard V Smith, Bradley A Schiff, Thomas J Ow, Madhur K Garg, Rafi Kabarriti, Vikas Mehta

{"title":"Association of tumor growth rate with overall survival and recurrence among patients with laryngeal squamous cell carcinoma.","authors":"Faye G Zhang, Shankar Viswanathan, Chenxin Zhang, Richard V Smith, Bradley A Schiff, Thomas J Ow, Madhur K Garg, Rafi Kabarriti, Vikas Mehta","doi":"10.1002/hed.27888","DOIUrl":null,"url":null,"abstract":"Background: Delay in time to treatment initiation (TTI) is associated with worsened survival outcomes in laryngeal squamous cell carcinoma (LSCC). It is unclear whether this is due to tumor growth or an increased risk of metastatic disease.Methods: This retrospective cohort study at one academic center included patients with LSCC who underwent radiotherapy/chemoradiotherapy between 2005 and 2017. We examined the association between tumor growth rate (TGR) and survival outcomes.Results: Among 105 patients (mean age, 63.8 ± 11.1 years; 72% male), the threshold between \"slow-growing\" and \"fast-growing\" tumors was >0.036 mL/day (survival) and >0.082 mL/day (recurrence). Faster growth was associated with worse overall survival (OS) (hazard ratio, 1.97; 95% confidence interval [CI], 0.94-4.13) and increased recurrence (odds ratio, 9.10; 95% CI, 2.40-34.4).Conclusions: TGR >0.036 mL/day during TTI was associated with decreased OS, and >0.082 mL/day was associated with increased recurrence. Tumor measurement in patients experiencing delay may identify those who could benefit from escalated therapy.","PeriodicalId":55072,"journal":{"name":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2024-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/hed.27888","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Delay in time to treatment initiation (TTI) is associated with worsened survival outcomes in laryngeal squamous cell carcinoma (LSCC). It is unclear whether this is due to tumor growth or an increased risk of metastatic disease.

Methods: This retrospective cohort study at one academic center included patients with LSCC who underwent radiotherapy/chemoradiotherapy between 2005 and 2017. We examined the association between tumor growth rate (TGR) and survival outcomes.

Results: Among 105 patients (mean age, 63.8 ± 11.1 years; 72% male), the threshold between "slow-growing" and "fast-growing" tumors was >0.036 mL/day (survival) and >0.082 mL/day (recurrence). Faster growth was associated with worse overall survival (OS) (hazard ratio, 1.97; 95% confidence interval [CI], 0.94-4.13) and increased recurrence (odds ratio, 9.10; 95% CI, 2.40-34.4).

Conclusions: TGR >0.036 mL/day during TTI was associated with decreased OS, and >0.082 mL/day was associated with increased recurrence. Tumor measurement in patients experiencing delay may identify those who could benefit from escalated therapy.

查看原文本刊更多论文

喉鳞状细胞癌患者的肿瘤生长率与总生存期和复发率的关系。

背景：延迟开始治疗的时间（TTI）与喉鳞状细胞癌（LSCC）生存结果的恶化有关。目前还不清楚这是由于肿瘤生长还是转移性疾病风险增加所致：这项在一家学术中心进行的回顾性队列研究纳入了2005年至2017年间接受放疗/化疗的LSCC患者。我们研究了肿瘤生长率（TGR）与生存结果之间的关系：在105名患者（平均年龄为63.8 ± 11.1岁；72%为男性）中，"生长缓慢 "和 "生长迅速 "肿瘤之间的临界值分别为>0.036 mL/天（生存）和>0.082 mL/天（复发）。生长速度越快，总生存期（OS）越差（危险比，1.97；95% 置信区间[CI]，0.94-4.13），复发率越高（几率比，9.10；95% CI，2.40-34.4）：结论：TTI期间TGR>0.036毫升/天与OS下降有关，>0.082毫升/天与复发增加有关。对出现延迟的患者进行肿瘤测量可确定哪些患者可从升级治疗中获益。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Head and Neck-Journal for the Sciences and Specialties of the Head and Neck 医学-耳鼻喉科学

CiteScore

7.00

自引率

6.90%

发文量

278

审稿时长

1.6 months

期刊介绍： Head & Neck is an international multidisciplinary publication of original contributions concerning the diagnosis and management of diseases of the head and neck. This area involves the overlapping interests and expertise of several surgical and medical specialties, including general surgery, neurosurgery, otolaryngology, plastic surgery, oral surgery, dermatology, ophthalmology, pathology, radiotherapy, medical oncology, and the corresponding basic sciences.